Home World News Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML World News Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML By Ogkologos - September 14, 2026 103 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PARADIGM study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Improving research with registered reports May 16, 2022 Jennifer Garner Shared A Video Of Her Mammogram Appointment October 21, 2019 Texting May Help Reduce Disparities in Colorectal Cancer Screening March 19, 2021 EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab September 3, 2024 Load more HOT NEWS Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk... EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab Some People with Rectal Cancer Can Skip Radiation Before Surgery Home Is Where the Heart Is
